UK markets closed

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.1958+0.0151 (+8.36%)
As of 01:49PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.1807
Bid0.1935 x 800
Ask0.1948 x 1100
Day's range0.1700 - 0.2104
52-week range0.1300 - 2.4500
Avg. volume1,944,761
Market cap16.545M
Beta (5Y monthly)0.46
PE ratio (TTM)N/A
EPS (TTM)-0.6380
Earnings date07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.67
  • Globe Newswire

    ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

    Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to resolve its current over-indebtedness position and to withdraw its pending Swiss moratorium proceedingsSale proceeds expected to position ObsEva to satisfy Nasdaq stockholders’ equity requirement for continued public listingObsEva expects to have greater than one year of cash runway, providing strateg

  • Globe Newswire

    ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings

    Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7 million of accounts payable assigned to date Company extends forbearance agreement with JGB through December 1, 2022Swiss court grants stay of moratorium proceedings through November 30, 2022, as ObsEva progresses restructuring initiatives Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchan

  • Globe Newswire

    ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s health, today announced that Yuyuan Bioscience’s (Yuyuan) IND application for a Phase 1 clinical trial of nolasiban has been approved by the Center for Drug Evaluation at the Chinese National Medical Products Administration. Nolasiban is a novel, oral oxytocin receptor antagonist being